Predictions
Novavax Inc.
Start price
Target price
Perf. (%)
€114.10
07.01.22
07.01.22
€130.00
07.01.23
07.01.23
-63.63%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Criteo S.A. ADR
Start price
Target price
Perf. (%)
€34.20
04.06.21
04.06.21
€36.00
04.06.22
04.06.22
-30.41%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
KKO International
Start price
Target price
Perf. (%)
€0.15
04.06.21
04.06.21
€0.20
04.06.22
04.06.22
-0.54%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Temenos AG ADR
Start price
Target price
Perf. (%)
€127.00
04.06.21
04.06.21
€125.00
04.06.22
04.06.22
-31.10%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Capital Bancorp Inc
Start price
Target price
Perf. (%)
€20.20
04.06.21
04.06.21
€20.00
04.06.22
04.06.22
5.94%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Canadian Solar Inc.
Start price
Target price
Perf. (%)
€29.55
31.05.22
31.05.22
€32.00
31.05.23
31.05.23
4.91%
04.06.22
04.06.22
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
Charles Schwab Corp.
Start price
Target price
Perf. (%)
€57.70
23.07.21
23.07.21
-
23.07.22
23.07.22
15.23%
04.06.22
04.06.22
negative Cash Flow expected
Revenue decline/stagnation expected
High valuation
Low dividend yield expected
Geratherm Medical AG
Start price
Target price
Perf. (%)
€9.46
03.10.21
03.10.21
-
03.10.22
03.10.22
-10.78%
04.06.22
04.06.22
Could be very worthwhile Investment >20% year
Saint Gobain S.A.
Start price
Target price
Perf. (%)
€57.60
03.06.21
03.06.21
€60.00
03.06.22
03.06.22
-2.97%
04.06.22
04.06.22
Could be worthwhile Investment >10% per year
Tritax Eurobox
Start price
Target price
Perf. (%)
€1.25
03.06.21
03.06.21
€2.00
03.06.22
03.06.22
-12.80%
04.06.22
04.06.22
Could be worthwhile Investment >10% per year
AstraZeneca plc
Start price
Target price
Perf. (%)
€91.61
03.06.21
03.06.21
€115.00
03.06.22
03.06.22
34.21%
04.06.22
04.06.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
Sunpower Corp.
Start price
Target price
Perf. (%)
€19.78
03.06.21
03.06.21
-
03.06.22
03.06.22
-11.95%
04.06.22
04.06.22
Could be very worthwhile Investment >20% year
Sustainability is important
Small cyclical dependencies
Future proof or reliable business model
Gazprom ADR
Start price
Target price
Perf. (%)
€6.18
06.08.19
06.08.19
€17.00
04.06.22
04.06.22
-36.18%
04.06.22
04.06.22
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Paypal Holdings Inc
Start price
Target price
Perf. (%)
€111.00
06.02.22
06.02.22
-
06.02.25
06.02.25
-27.25%
03.06.22
03.06.22
Could be worthwhile Investment >10% per year
Freelance.com
Start price
Target price
Perf. (%)
€5.66
19.06.21
19.06.21
€7.00
02.06.22
02.06.22
29.33%
03.06.22
03.06.22
Could be worthwhile Investment >10% per year
Advanced Micro Devices Inc.
Start price
Target price
Perf. (%)
€67.39
03.06.21
03.06.21
€150.00
03.06.22
03.06.22
50.59%
03.06.22
03.06.22
Mobotix AG
Start price
Target price
Perf. (%)
€5.95
02.06.21
02.06.21
€7.00
02.06.22
02.06.22
-31.76%
03.06.22
03.06.22
Could be worthwhile Investment >10% per year
Noxxon Pharma N.v.
Start price
Target price
Perf. (%)
€0.24
12.11.21
12.11.21
€0.38
12.11.22
12.11.22
-51.77%
02.06.22
02.06.22
Could be worthwhile Investment >10% per year
Citigroup Inc.
Start price
Target price
Perf. (%)
€58.95
12.09.21
12.09.21
-
12.09.22
12.09.22
-17.26%
02.06.22
02.06.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
High dividend yield expected
Bone Therapeutics S.A.
Start price
Target price
Perf. (%)
€1.56
10.09.21
10.09.21
€2.00
10.09.22
10.09.22
-82.43%
02.06.22
02.06.22
Could be worthwhile Investment >10% per year
Protalix Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€1.76
04.04.22
04.04.22
€0.000
04.04.23
04.04.23
-35.27%
02.06.22
02.06.22
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline > 20% expected
overvalued